StudyFinder

MT2025-51: A RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FOR LARGE B-CELL LYMPHOMA (ALPHA3)

Status: Recruiting

This study is for adults with large B-cell lymphoma whose cancer responded to standard treatment but still shows small amounts of disease on a specialized blood test. Participants will be randomly assigned to receive either an investigational CAR T-cell therapy or standard follow-up observation to compare safety and how well each approach helps prevent the lymphoma from returning.

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18 years of age or older
• diagnosed with certain types of large B-cell lymphoma (LBCL)
• completed standard first-line treatment without needing additional therapy
• cancer is in complete remission or partial remission suitable for observation after first-line treatment
Exclusion Criteria:

• lymphoma has spread to the brain or spinal cord, or developed from another type of cancer
• previously treated with anti-CD19 therapy
• active autoimmune disease or a serious infection requiring treatment
• another cancer or bone marrow disorder diagnosed within the past 3 years
Interventions:

Drug: Cyclophosphamide, Drug: Fludarabine, Device: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™, Genetic: cemacabtagene ansegedleucel

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Cancer, large B-cell lymphoma, LBCL

Study Contact: Veronika Bachanova - bach0173@umn.edu
Principal Investigator: Veronika Bachanova, MD
Phase: PHASE2
IRB Number: STUDY00027450
See this study on ClinicalTrials.gov

Back